ES2187798T3 - Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. - Google Patents
Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.Info
- Publication number
- ES2187798T3 ES2187798T3 ES97933740T ES97933740T ES2187798T3 ES 2187798 T3 ES2187798 T3 ES 2187798T3 ES 97933740 T ES97933740 T ES 97933740T ES 97933740 T ES97933740 T ES 97933740T ES 2187798 T3 ES2187798 T3 ES 2187798T3
- Authority
- ES
- Spain
- Prior art keywords
- viral
- conservation
- procedure
- recombinant viruses
- medicinal product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000002458 infectious effect Effects 0.000 title abstract 3
- 239000000725 suspension Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9608851A FR2751343B1 (fr) | 1996-07-16 | 1996-07-16 | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2187798T3 true ES2187798T3 (es) | 2003-06-16 |
Family
ID=9494078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97933740T Expired - Lifetime ES2187798T3 (es) | 1996-07-16 | 1997-07-15 | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6451256B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0853660B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP3681401B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE231549T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU711409B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2232604C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69718612T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0853660T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2187798T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2751343B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998002522A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| AU773834B2 (en) * | 1998-12-03 | 2004-06-10 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6225289B1 (en) * | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| JP2002541792A (ja) | 1999-04-09 | 2002-12-10 | アベンテイス・フアルマ・ソシエテ・アノニム | 感染性の組換えアデノウイルスの保存用組成物 |
| FR2791999B1 (fr) * | 1999-04-09 | 2001-09-07 | Aventis Pharma Sa | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| EP1263461A4 (en) | 2000-03-07 | 2009-08-12 | Merck & Co Inc | ADENOVIRUS FORMULATIONS |
| WO2001085928A1 (en) * | 2000-05-10 | 2001-11-15 | Mitsubishi Pharma Corporation | Method of preparing virus vector |
| WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| EP1465664A1 (en) * | 2002-01-18 | 2004-10-13 | Schering Aktiengesellschaft | Stabilized formulations of adenovirus |
| KR100507794B1 (ko) * | 2003-02-11 | 2005-08-17 | 한미약품 주식회사 | 고농도 레트로 바이러스 현탁액 제조 방법 |
| US20070148765A1 (en) * | 2003-11-19 | 2007-06-28 | Evans Robert K | Preservative-containing virus formulations |
| ES2329607T3 (es) * | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
| GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| CA2602944C (en) * | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| KR101820980B1 (ko) | 2010-02-15 | 2018-01-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Ａｄ 26 아데노바이러스 벡터를 제조하는 방법 |
| WO2012038367A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
| CN103347535B (zh) | 2010-12-02 | 2015-11-25 | 昂科利蒂克斯生物科技公司 | 液体病毒制剂 |
| EP2646052B1 (en) | 2010-12-02 | 2017-03-29 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| KR102044051B1 (ko) | 2012-03-12 | 2019-11-12 | 얀센 백신스 앤드 프리벤션 비.브이. | 터미널 말단이 변경된 재조합 아데노바이러스의 배치 |
| JP5805908B2 (ja) | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| KR20150058152A (ko) | 2012-07-10 | 2015-05-28 | 트랜스진 에스아이 | 마이코박테리아 항원 백신 |
| AU2014259474B2 (en) | 2013-04-25 | 2018-09-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble prefusion RSV F polypeptides |
| EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| CN106103471B (zh) | 2014-01-09 | 2020-01-07 | 特兰斯吉恩股份有限公司 | 异源寡聚分枝杆菌抗原的融合 |
| US9721484B2 (en) | 2014-06-23 | 2017-08-01 | Humanetics Innovative Solutions, Inc. | Shoulder kit assembly for crash test dummy |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| US10008130B2 (en) | 2014-09-17 | 2018-06-26 | Humanetics Innovative Solutions, Inc. | Omni-directional shoulder assembly for crash test dummy |
| EP3256156B1 (en) | 2015-02-13 | 2025-02-12 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| SI3283634T1 (sl) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem |
| AU2016289492B2 (en) | 2015-07-07 | 2022-08-11 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| CA2991540A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides |
| PT3439672T (pt) | 2016-04-05 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv |
| WO2017174564A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
| AU2017264562B2 (en) | 2016-05-12 | 2023-03-09 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| AU2017283118B2 (en) | 2016-06-20 | 2019-02-07 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| SG11201906271QA (en) | 2017-02-09 | 2019-08-27 | Janssen Vaccines & Prevention Bv | Potent and short promoter for expression of heterologous genes |
| EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3875119A4 (en) | 2018-10-30 | 2022-08-31 | The University of Tokyo | ONCOLYTIC VIRUS FOR CANCER THERAPY |
| PH12021550974A1 (en) | 2018-11-13 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Stablized pre-fusion rsv f proteins |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| MA71423A (fr) | 2020-03-19 | 2025-04-30 | Trizell Ltd. | Système de stockage de virus sensible à la température |
| WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
| IL304904A (en) | 2021-02-01 | 2023-10-01 | St Phi Therapeutics Co Ltd | Target protein degradation system and its use |
| AU2022221983A1 (en) | 2021-02-19 | 2023-08-17 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| JP2025523573A (ja) | 2022-07-01 | 2025-07-23 | トランジェーヌ | サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質 |
| CN120380015A (zh) | 2022-08-18 | 2025-07-25 | 特兰斯吉恩公司 | 嵌合痘病毒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5658779A (en) * | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
| CA2158935A1 (en) * | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| FR2711523B1 (fr) * | 1993-10-26 | 1996-02-16 | Transgene Sa | Procédé de préparation d'un aérosol viral. |
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
-
1996
- 1996-07-16 FR FR9608851A patent/FR2751343B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-15 DE DE69718612T patent/DE69718612T2/de not_active Expired - Lifetime
- 1997-07-15 US US09/043,187 patent/US6451256B1/en not_active Expired - Lifetime
- 1997-07-15 CA CA002232604A patent/CA2232604C/fr not_active Expired - Lifetime
- 1997-07-15 JP JP50569198A patent/JP3681401B2/ja not_active Expired - Lifetime
- 1997-07-15 AT AT97933740T patent/ATE231549T1/de active
- 1997-07-15 DK DK97933740T patent/DK0853660T3/da active
- 1997-07-15 WO PCT/FR1997/001308 patent/WO1998002522A1/fr not_active Ceased
- 1997-07-15 ES ES97933740T patent/ES2187798T3/es not_active Expired - Lifetime
- 1997-07-15 AU AU36986/97A patent/AU711409B2/en not_active Expired
- 1997-07-15 EP EP97933740A patent/EP0853660B1/fr not_active Expired - Lifetime
-
2002
- 2002-08-15 US US10/218,564 patent/US20030082206A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2232604C (fr) | 2005-06-28 |
| JP2000500026A (ja) | 2000-01-11 |
| DE69718612T2 (de) | 2003-11-06 |
| JP3681401B2 (ja) | 2005-08-10 |
| WO1998002522A1 (fr) | 1998-01-22 |
| US20030082206A1 (en) | 2003-05-01 |
| US6451256B1 (en) | 2002-09-17 |
| FR2751343B1 (fr) | 1998-12-18 |
| AU3698697A (en) | 1998-02-09 |
| FR2751343A1 (fr) | 1998-01-23 |
| ATE231549T1 (de) | 2003-02-15 |
| EP0853660B1 (fr) | 2003-01-22 |
| DE69718612D1 (de) | 2003-02-27 |
| CA2232604A1 (fr) | 1998-01-22 |
| AU711409B2 (en) | 1999-10-14 |
| EP0853660A1 (fr) | 1998-07-22 |
| DK0853660T3 (da) | 2003-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2187798T3 (es) | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. | |
| DE60239394D1 (de) | Onkolytische virustherapie | |
| KR20030025907A (ko) | 카세인 유도 펩타이드 및 이들의 치료 용도 | |
| UA66744C2 (en) | 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections | |
| SG17493G (en) | Ozone decontamination of blood and blood products | |
| ES2114073T3 (es) | Regeneracion del higado inducida por morfogenes. | |
| FI961536A0 (fi) | Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste | |
| DE60009146D1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten | |
| DE69914911D1 (de) | Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen | |
| EA199800526A1 (ru) | Производные бензимидазола и их применение для лечения вирусных инфекций | |
| DE69833876D1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
| KR20040078639A (ko) | 카세인 유도 펩타이드 및 이들의 치료 용도 | |
| AU2251302A (en) | Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 | |
| ITMI913493A0 (it) | Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus | |
| BG100835A (bg) | Ново лекарствено средство за лечение на вирусни инфекции на дихателните пътища | |
| ATE306275T1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten | |
| DE60040910D1 (de) | Inaktivierte zytokine zur immunisierung | |
| ATE497784T1 (de) | Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen | |
| DE69803052D1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
| RU98117264A (ru) | Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови | |
| UA10281C2 (uk) | Спосіб отримання речовини для лікування захворювань підшлункової залози | |
| MX9603241A (es) | Productos farmaceuticos para curar enfermedades tumorales y procedimiento para su preparacion. |